Based on these results ex vivo, we have conducted phase I clinical trials assessing the adverse event and efficacy of Survivin-2B80-88 peptide vaccination in patients with advanced colorectal cancer, breast cancer, lung cancer, bladder cancer, and oral cancer [24-26]. The gene discussed is BIRC5; the disease is lip and oral cavity carcinoma.